Genetic engineering, medical innovations, and biotechnology research
StrainX Bioworks' $13M round and Alt Carbon's Microsoft carbon-removal offtake rest on the same bet: India's fermentation costs run a third to a quarter of the West, turning a cost base into a manufacturing moat.
Manik Gupta
Author
India now has two approved indigenous CAR-T therapies priced an order of magnitude below the West. With Cipla's first export deal and Immuneel's ₹100 crore Series B, the binding constraint is no longer science but reimbursement.
Manik Gupta
Author
Serum Institute and Oxford's Jenner Institute have licensed R78C, a multi-stage malaria vaccine targeting two blood-stage antigens for more durable protection than single-antigen R21, pairing frontier antigen science with LMIC-scale manufacturing.
Manik Gupta
Author
India's bioeconomy hit $195.3 billion in 2025. The new ₹2,000 crore BIRAC-RDI Fund and the BioE3 policy's shared biofoundries target the country's real bottleneck for synbio founders: scale-up capex, not science.
Manik Gupta
Author
ICAR's SDN-1 gene-edited rice sidesteps GM regulation while claiming 19% higher yields, and GenomeIndia opens a 10,000-genome dataset, marking an Indian agri-biotech base built on indigenous tools and data.
Manik Gupta
Author
BIRSA 101, India's first indigenous CRISPR therapy for sickle cell, and a Vellore haemophilia trial reporting a zero bleeding rate in NEJM together turn the country's gene-therapy ambition into an investable, population-scale platform.
Manik Gupta
Author
